Basic Mercilon Information

• INN (International Nonproprietary Name): Desogestrel and Ethinyl Estradiol
• Brand Names Available In United Kingdom: Mircette (USA discontinued; available in some international markets), Kariva (USA generic), Azurette (USA generic) and other generics such as Bekyree, Kimidess, Pimtrea and Viorele that mirror the Mircette biphasic design.
• ATC Code: G03AA11 (Sex hormones and modulators; Progestogens and estrogens, fixed combinations; Desogestrel and Ethinyl Estradiol)
• Forms & Dosages: Tablet — 21 active tablets containing 0.15 mg desogestrel + 0.02 mg ethinyl estradiol, 2 inert tablets, and 5 tablets with 0.01 mg ethinyl estradiol; oral, once daily in a 28‑day pack.
• Manufacturers In United Kingdom: Former brand holder included Duramed/Barr Laboratories (USA, discontinued); generics and international versions are manufactured by Teva, Amneal, Aurobindo, Zydus and Lupin — availability in the UK depends on MHRA marketing authorisation.
• Registration Status In United Kingdom: Not specified — clinicians and pharmacists should verify UK marketing authorisation via the MHRA and local formularies before prescribing or supplying.
• OTC / Rx Classification: Prescription (Rx only) in all jurisdictions according to product information sources.

Key Findings From Recent Trials

Major 2022–2025 Studies

Clinicians want to know if newer data change practice for combined desogestrel and ethinyl estradiol pills.

Large observational cohorts and pharmacovigilance analyses from 2022 to 2025 focused on real‑world effectiveness and bleeding patterns.

Comparative cohort studies examined Mircette/Kariva‑style biphasic regimens against other combined oral contraceptives to assess cycle control and tolerability.

Studies consistently used typical‑use outcome measures and monitored venous thromboembolism (VTE) signals across databases.

Main Outcomes

When taken correctly, desogestrel plus ethinyl estradiol formulations show contraceptive effectiveness comparable with other combined oral contraceptives.

Early cycle irregular bleeding is a frequent observation but tends to improve after around three months of continuous use.

Adherence and clinician counselling in primary care audits improved continuation and satisfaction rates.

Safety Observations

Safety surveillance maintained the established class signal for increased VTE risk with oestrogen‑containing combined pills.

Regulatory reviews of EMA and FDA datasets emphasised contraindications in high‑risk groups such as smokers over 35 and those with prior thrombosis.

No new mechanistic safety signal specific to the Mircette/Kariva biphasic regimen was identified in the reviewed period, but post‑marketing monitoring remains advised.

Clinical Mechanism Of Action

Layman’s Explanation

Patients often ask how this pill prevents pregnancy in plain terms.

Mercilon‑style pills combine a progestogen (desogestrel) with a low dose of oestrogen (ethinyl estradiol) to stop ovulation, thicken cervical mucus and change the womb lining so implantation is less likely.

The combined effects make it hard for an egg to develop, for sperm to reach an egg and for a fertilised egg to implant.

Scientific Breakdown

Desogestrel is a third‑generation progestogen usually dosed at 0.15 mg per active tablet, and ethinyl estradiol is present at 0.02 mg in most active tablets with some low‑dose tablets at 0.01 mg.

Desogestrel is converted rapidly to the active metabolite etonogestrel which has potent ovulation‑suppressing activity.

Pharmacodynamics

The combined pill suppresses the hypothalamic‑pituitary‑ovarian axis, reducing follicular development and preventing the LH surge required for ovulation.

The progestogen thickens cervical mucus and alters endometrial receptivity, providing multiple contraceptive mechanisms.

Pharmacokinetics

Desogestrel is metabolised to etonogestrel after oral absorption and ethinyl estradiol undergoes first‑pass hepatic metabolism which affects sex‑hormone‑binding globulin and coagulation factors.

The hepatic influence on clotting proteins partly explains the class VTE risk associated with combined oestrogen‑containing pills.

The biphasic 28‑day pack (21 active, 2 inert, 5 low‑dose ethinyl estradiol) aims to balance withdrawal bleeding predictability with tolerability.

Scope Of Approved And Off‑Label Use

United Kingdom Approvals

Healthcare professionals need clear boundaries for licensed uses.

The desogestrel plus ethinyl estradiol fixed combination is indicated for contraception only in its licensed summaries.

Packs that follow the Mircette/Kariva biphasic design are prescription‑only and their UK availability should be confirmed with the MHRA and BNF.

Clinicians may prescribe generics authorised in the EU or UK where marketing authorisation exists and local formularies permit.

Notable Off‑Label Trends

Off‑label use is commonly seen for cycle regulation, dysmenorrhoea and acne where the oestrogen component provides benefit.

Adolescents post‑menarche typically receive standard dosing; use in pre‑menarche is not recommended.

Continuous back‑to‑back use (skipping breaks) is increasingly adopted to manage heavy or painful bleeding, but clear counselling and monitoring are required.

Dosage Strategy

General Dosing

Prescribers commonly ask about starting options and daily timing for optimal effect.

The standard regimen is one tablet once daily at the same time from a 28‑day pack containing 21 active tablets (0.15 mg desogestrel + 0.02 mg ethinyl estradiol), 2 inert tablets, and 5 low‑dose ethinyl estradiol tablets (0.01 mg).

Start options include Day‑1 start or Sunday start as per pack instructions, and continuous use is possible by starting the next pack immediately without a pill‑free interval.

Condition‑Specific Dosing

Adolescents post‑menarche use the standard adult dosing; there is no specific licensed dose reduction for children or elderly as the products are for contraceptive use.

Severe hepatic disease is a contraindication and renal impairment data are limited; alternatives are preferred in severe organ impairment.

Missed pill guidance: one missed tablet should be taken as soon as remembered and normal schedule resumed, which may mean taking two tablets in one day.

Multiple missed active tablets require following the specific pack instructions, consideration of emergency contraception and use of barrier methods until seven consecutive active pills have been taken.

Overdose management is symptomatic; nausea, vomiting or withdrawal bleeding may occur.

Safety Protocols

Contraindications

Safety checks must be completed before prescribing a combined pill.

Absolute contraindications include pregnancy, previous thromboembolic events such as DVT, PE, stroke or myocardial infarction, severe hepatic impairment or liver tumours, uncontrolled hypertension, migraine with aura, smoking in those over 35 years, known hormone‑dependent malignancy, undiagnosed abnormal genital bleeding and hypersensitivity to components.

Relative contraindications—requiring individual risk assessment—include controlled hypertension, diabetes with vascular complications, hyperlipidaemia, certain migraine patterns, strong family history of thrombosis, obesity and prolonged immobilisation.

Adverse Effects

Common adverse effects reported in clinical use and SPCs include headache, nausea, breast tenderness and irregular bleeding or spotting, especially in early cycles.

Mood changes, mild fluid retention and weight fluctuations are described and less common events include hypertension, acne and decreased libido.

Baseline blood pressure measurement and a VTE risk assessment are recommended prior to initiation, with review at around three months and then annually unless clinical circumstances require earlier review.

Advise patients clearly on VTE warning signs and to seek urgent medical review for symptoms such as unilateral leg pain or sudden breathlessness.

Interaction Mapping

Food Interactions

Patients often worry whether to take the pill with food.

There are no clinically significant food‑drug interactions documented for desogestrel and ethinyl estradiol; absorption is not food dependent.

Severe vomiting or diarrhoea can impair absorption and patients should follow missed‑pill or emergency contraception guidance in those circumstances.

Drug Combinations To Avoid

The primary interaction concern is reduced contraceptive effectiveness with enzyme‑inducing medicines.

Medications such as carbamazepine, phenytoin, primidone, rifampicin/rifabutin, some antiretrovirals and St John’s wort can lower steroid levels and increase the risk of unintended pregnancy.

Most common antibiotics that are not enzyme inducers do not require routine additional contraception, with rifampicin/rifabutin as the main exception.

Strong CYP3A4 inducers or inhibitors may alter ethinyl estradiol metabolism and coagulation factor exposure; check the BNF or SPC before prescribing and advise alternative or barrier methods where indicated.

Patient Experience Analysis

Survey Data

Patients frequently ask how others tolerate the pill and what side effects to expect.

Real‑world surveys show high satisfaction for contraceptive reliability and good cycle predictability after the initial adjustment period of two to three cycles.

Early complaints commonly include irregular bleeding and nausea, which often settle with continued use.

Primary‑care audits in the UK indicate that thorough counselling on side effects and missed‑pill procedures improves adherence and continuation.

Forum Trends

Online communities report mixed experiences with Mercilon‑style pills; some users praise predictable cycles and tolerability while others report mood changes or persistent spotting.

Many patients who experience ongoing bleeding or mood symptoms switch to alternative combined pills or progestogen‑only methods after clinician review.

Clinicians should pre‑emptively counsel that early irregular bleeding is common, schedule a review at three months and offer SRH or GP follow‑up for persistent adverse effects.

Distribution And Pricing Landscape

Market Availability

Supply and brand names have shifted since the original Mircette launch.

Mircette was discontinued in the USA but Mircette‑style biphasic packs exist as generics such as Kariva and Azurette and in EU markets under other generic names.

Manufacturers producing generics include Teva, Amneal, Aurobindo and Lupin, and clinicians should confirm MHRA authorisation and local formulary listings before prescribing.

Cost & Reimbursement In UK

Combined oral contraceptives are prescription‑only and many clinics and NHS contraception services provide them free of charge to eligible patients.

Private prescription costs vary by pharmacy and brand, with generics typically costing less than branded products.

Prescribers should check local ICS/CCG formularies for supply continuity and advise patients about replacement packs when travelling and correct storage below 25°C.

In our online pharmacy, mercilon is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Alternative Options

Comparison Table

Choosing the right method depends on risk profile, bleeding preference and adherence likelihood.

Marvelon (desogestrel/ethinyl estradiol, different dose/regimen) can be considered for tuning bleeding control.

Drospirenone/ethinyl estradiol (Yasmin) may help fluid retention and acne but has a distinct VTE risk profile to discuss with patients.

Progestogen‑only pills such as Cerazette or Cerelle (desogestrel‑only) are suitable when oestrogen is contraindicated, for example during breastfeeding or with high VTE risk, but require strict timing and may have different bleeding patterns.

Non‑oral options such as the vaginal ring, patches, implants and intrauterine devices avoid daily dosing and can help adherence challenges.

Pros And Cons

Desogestrel plus ethinyl estradiol combinations reliably suppress ovulation and provide oestrogen‑derived cycle control while retaining familiar oral administration.

Drawbacks include oestrogen‑associated VTE risk and a higher likelihood of early irregular bleeding for some users.

Individualised counselling considering smoking status, BMI, age and family history of thrombosis is essential before selection.

Regulatory Status

International Registrations

The combination is coded under ATC G03AA11 and has multiple generic registrations across regulatory regions.

FDA records show historical approval for Mircette with product code 020713 while branded Mircette is discontinued in the USA but generics like Kariva and Azurette remain available.

EMA and national EU regulators list multiple generics, and manufacturers include Teva, Amneal, Aurobindo, Zydus and Lupin.

UK Regulatory Notes

In the post‑Brexit context clinicians must confirm which generics hold MHRA marketing authorisation before prescribing in the UK.

Legal classification is prescription‑only and pharmacovigilance reports should be submitted via the Yellow Card scheme for suspected adverse reactions.

Consult the SPC and patient information leaflet associated with the specific UK marketing authorisation for up‑to‑date contraindications and safety information.

Consolidated FAQ

Top Patient Questions

Is Mercilon available in the UK?

The original Mircette or Mercilon brand may be discontinued regionally, but equivalent generics (Kariva, Azurette and others) with the same 28‑day biphasic pack are available; check MHRA and BNF listings for local availability.

How effective is it?

When used correctly it is highly effective, and typical‑use failure rates are comparable with other combined oral contraceptives.

Clinician Quick Answers

Can I use it when breastfeeding?

Combined pills containing ethinyl estradiol are generally not recommended early postpartum or during breastfeeding; consider progestogen‑only methods for those who are breastfeeding.

What about blood clots?

Combined oestrogen‑containing pills increase VTE risk and are contraindicated in patients with prior thromboembolism or high‑risk profiles.

Missed pill advice?

One missed pill — take as soon as remembered and continue; multiple missed actives — follow the specific pack SPC and consider emergency contraception and barrier back‑up until seven consecutive actives have been taken.

Visual Guide

What Diagrams Should Include

Clinicians and patient educators benefit from clear, labelled visuals when explaining a biphasic pack.

Essential diagrams include a pack composition diagram showing 21 active tablets (0.15 mg desogestrel + 0.02 mg ethinyl estradiol), 2 inert tablets and 5 low‑dose ethinyl estradiol tablets measuring 0.01 mg, with arrows indicating daily sequence.

A missed‑pill flowchart that distinguishes one missed tablet from multiple missed actives and the actions per week is highly useful for both patients and staff.

Patient‑Facing Infographic Elements

Include a contraindication checklist with icons for smoker over 35, VTE history, migraine with aura and severe liver disease.

Warning icons for VTE symptoms — leg swelling or pain, chest pain, sudden breathlessness — should be prominent and paired with clear action steps to seek urgent care.

Storage advice (keep below 25°C in original blister) and Yellow Card reporting signposts should appear on patient materials.

Storage And Transport

Pharmacy Handling

Pharmacies must store mercilon packs in original packaging at temperatures below 25°C and protect them from moisture and light.

Suppliers and wholesalers provide standard SPC storage instructions and pharmacy teams should follow manufacturer guidance when receiving stock.

During transport avoid excessive heat; use insulated carriers in hot weather and perform inventory checks after extreme temperature exposure.

Patient Storage Guidance

Advise patients to keep packs in a cool, dry place out of sight of children and to retain pills in the original blister to preserve the daily order.

Do not refrigerate tablets and replace packs that have been exposed to extreme heat, for example left in a hot car.

Expired or unwanted packs should be returned to a pharmacy for appropriate disposal rather than being flushed or thrown in household waste.

Guidelines For Proper Use

Prescribing Checklist

Ensure pregnancy is excluded before starting an oestrogen‑containing combined pill.

Screen for VTE risk factors including personal and family history, current smoking status, BMI and any migraine with aura history.

Measure baseline blood pressure and review liver disease history; check concomitant medications for enzyme inducers and document informed consent along with discussed alternatives.

Counselling Script Bullets

Take one tablet daily at the same time each day and follow the pack order of 21 active tablets, 2 inert tablets and 5 low‑dose tablets.

Explain what to do in the event of vomiting or severe diarrhoea and give clear missed‑pill instructions tailored to the week of the cycle.

Discuss VTE warning signs and advise review at three months and then annually or sooner if concerns arise.

Provide written information, signpost NHS sexual health services and the Yellow Card scheme, and emphasise that generics may vary in appearance but not in therapeutic effect.

Delivery Across United Kingdom